HLA-B27 and Clinical Characteristics of Reactive Arthritis

B27- (6%) patients (p<0.05). During acute RD, mucocutaneous symptoms were the only manifestation more frequent in B27+ (50%) thaninB27- (17%)RDpatients(p<0.01). At the follow-up study mean 6 years later, peripheral joint symptoms occurred in two thirds of the RD patients with or without HLA-B27. Back pain was slightly more common in B27+ patients (44% vs. 22%; NS).